首页 > 最新文献

Pediatric Blood & Cancer最新文献

英文 中文
The medical and functional burden of surviving childhood ependymoma: A population-based study in Ontario, Canada 儿童脑外胶质瘤患者的医疗和功能负担:加拿大安大略省的一项人口研究。
IF 2.4 3区 医学 Q2 HEMATOLOGY Pub Date : 2024-08-16 DOI: 10.1002/pbc.31275
Hallie Coltin, Priscila Pequeno, Ning Liu, Derek S. Tsang, Sumit Gupta, Michael D. Taylor, Eric Bouffet, Vijay Ramaswamy, Paul C. Nathan

Background

Few studies have characterized the burden of late effects among childhood ependymoma survivors. To address this gap, we examined these sequelae using real-world health services data in a population-based ependymoma survivor cohort.

Methods

All individuals younger than 18 years diagnosed with an ependymoma in Ontario, Canada between 1987 and 2015 who had survived at least 5 years from their latest pediatric cancer event (index date) were matched 1:5 with population controls. Following linkage with provincial health services data, the cumulative incidences of multiple medical and functional outcomes between survivors and controls were compared.

Results

Among 96 survivors, 77.1% had been irradiated and 9.4% had received cisplatin. At 10 years post-index, survivors were at significantly higher risk of all-cause mortality (7.1%, 95% confidence interval [CI]: 1.0–13.3 vs. 0.3%, 95% CI: 0.0–1.0; p = .0002), non-obstetric hospitalization (45.1%, 95% CI: 32.6–56.7 vs. 10.6%, 95% CI: 7.6–14.1; p < .0001), stroke (6.5%, 95% CI: 2.3–13.7 vs. 0%; p < .0001), severe hearing loss requiring an amplification device (7.5%, 95% CI: 2.7–15.7 vs. 0%; p < .0001), receiving homecare service (27.6%, 95% CI: 18.5–37.5 vs. 7.7%, 95% CI: 5.3–10.7; p < .0001), and submitting a disability support prescription claim (24.0%, 95% CI: 14.8–34.3 vs. 5.4%, 95% CI: 3.5–7.8; p < .0001) compared to controls.

Conclusions

Pediatric ependymoma survivors are highly vulnerable to severe late sequelae, including death, stroke, severe hearing loss, and disability. Urgent efforts are needed to improve risk-stratification approaches that mitigate exposure to toxic therapies for children with lower risk disease. Interventions to prevent or decrease the risk of developing late sequelae are critical to optimizing survivor long-term health.

背景:很少有研究描述过儿童脑外胶质瘤幸存者的后遗症负担。为了填补这一空白,我们利用基于人群的脑外膜瘤幸存者队列中的真实医疗服务数据,对这些后遗症进行了研究:方法:1987 年至 2015 年间,加拿大安大略省所有年龄小于 18 岁、被诊断患有附乳瘤且从最近一次儿科癌症事件(索引日期)起存活至少 5 年的患者均与人群对照组进行了 1:5 匹配。在与省级医疗服务数据连接后,比较了幸存者和对照组之间多种医疗和功能结果的累积发生率:在 96 名幸存者中,77.1% 接受过辐照,9.4% 接受过顺铂治疗。在指数发布后 10 年,幸存者的全因死亡风险明显更高(7.1%,95% 置信区间 [CI]:1.0-13.3 vs. 0.3%,95% CI:0.0-1.0;p = .0002)、非产科住院(45.1%,95% CI:32.6-56.7 vs. 10.6%,95% CI:7.6-14.1;p 结论:小儿脑上皮瘤幸存者极易出现严重的晚期后遗症,包括死亡、中风、严重听力损失和残疾。亟需改进风险分级方法,以减少风险较低的患儿接触有毒疗法的机会。预防或降低罹患晚期后遗症风险的干预措施对于优化幸存者的长期健康至关重要。
{"title":"The medical and functional burden of surviving childhood ependymoma: A population-based study in Ontario, Canada","authors":"Hallie Coltin,&nbsp;Priscila Pequeno,&nbsp;Ning Liu,&nbsp;Derek S. Tsang,&nbsp;Sumit Gupta,&nbsp;Michael D. Taylor,&nbsp;Eric Bouffet,&nbsp;Vijay Ramaswamy,&nbsp;Paul C. Nathan","doi":"10.1002/pbc.31275","DOIUrl":"10.1002/pbc.31275","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Few studies have characterized the burden of late effects among childhood ependymoma survivors. To address this gap, we examined these sequelae using real-world health services data in a population-based ependymoma survivor cohort.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>All individuals younger than 18 years diagnosed with an ependymoma in Ontario, Canada between 1987 and 2015 who had survived at least 5 years from their latest pediatric cancer event (index date) were matched 1:5 with population controls. Following linkage with provincial health services data, the cumulative incidences of multiple medical and functional outcomes between survivors and controls were compared.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 96 survivors, 77.1% had been irradiated and 9.4% had received cisplatin. At 10 years post-index, survivors were at significantly higher risk of all-cause mortality (7.1%, 95% confidence interval [CI]: 1.0–13.3 vs. 0.3%, 95% CI: 0.0–1.0; <i>p</i> = .0002), non-obstetric hospitalization (45.1%, 95% CI: 32.6–56.7 vs. 10.6%, 95% CI: 7.6–14.1; <i>p</i> &lt; .0001), stroke (6.5%, 95% CI: 2.3–13.7 vs. 0%; <i>p</i> &lt; .0001), severe hearing loss requiring an amplification device (7.5%, 95% CI: 2.7–15.7 vs. 0%; <i>p</i> &lt; .0001), receiving homecare service (27.6%, 95% CI: 18.5–37.5 vs. 7.7%, 95% CI: 5.3–10.7; <i>p</i> &lt; .0001), and submitting a disability support prescription claim (24.0%, 95% CI: 14.8–34.3 vs. 5.4%, 95% CI: 3.5–7.8; <i>p</i> &lt; .0001) compared to controls.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Pediatric ependymoma survivors are highly vulnerable to severe late sequelae, including death, stroke, severe hearing loss, and disability. Urgent efforts are needed to improve risk-stratification approaches that mitigate exposure to toxic therapies for children with lower risk disease. Interventions to prevent or decrease the risk of developing late sequelae are critical to optimizing survivor long-term health.</p>\u0000 </section>\u0000 </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.31275","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141996251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia Venetoclax 用于治疗新确诊的急性髓性白血病儿科患者。
IF 2.4 3区 医学 Q2 HEMATOLOGY Pub Date : 2024-08-16 DOI: 10.1002/pbc.31286
Amber Gibson, Samantha Dickson, David McCall, Miriam Garcia, Jeremy Connors, Jiasen He, Michael Roth, Cesar Nunez, Branko Cuglievan

This retrospective study at the University of Texas MD Anderson Cancer Center evaluated frontline venetoclax combination therapy in 11 pediatric/adolescent patients with acute myeloid leukemia (AML). Despite the small sample size and retrospective nature, the treatment demonstrated safety and potential efficacy, with most patients achieving early complete remission. Adverse events were consistent with other AML therapies, and no discontinuations due to toxicity occurred. While acknowledging study limitations, including selection bias and diverse concurrent therapies, this research underscores the promising role of venetoclax in pediatric AML. Further investigation is crucial to validate its long-term efficacy in this population.

德克萨斯大学 MD 安德森癌症中心的这项回顾性研究评估了 11 名急性髓性白血病(AML)儿童/青少年患者的一线 venetoclax 联合疗法。尽管样本量较小,而且是回顾性研究,但该疗法显示出安全性和潜在疗效,大多数患者都实现了早期完全缓解。不良反应与其他急性髓细胞白血病疗法一致,没有出现因毒性而停药的情况。这项研究承认研究存在局限性,包括选择偏倚和多种并发疗法,但它强调了 Venetoclax 在小儿急性髓细胞性白血病中的前景。进一步的研究对于验证其在这一人群中的长期疗效至关重要。
{"title":"Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia","authors":"Amber Gibson,&nbsp;Samantha Dickson,&nbsp;David McCall,&nbsp;Miriam Garcia,&nbsp;Jeremy Connors,&nbsp;Jiasen He,&nbsp;Michael Roth,&nbsp;Cesar Nunez,&nbsp;Branko Cuglievan","doi":"10.1002/pbc.31286","DOIUrl":"10.1002/pbc.31286","url":null,"abstract":"<p>This retrospective study at the University of Texas MD Anderson Cancer Center evaluated frontline venetoclax combination therapy in 11 pediatric/adolescent patients with acute myeloid leukemia (AML). Despite the small sample size and retrospective nature, the treatment demonstrated safety and potential efficacy, with most patients achieving early complete remission. Adverse events were consistent with other AML therapies, and no discontinuations due to toxicity occurred. While acknowledging study limitations, including selection bias and diverse concurrent therapies, this research underscores the promising role of venetoclax in pediatric AML. Further investigation is crucial to validate its long-term efficacy in this population.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141996252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of neonatal and infant aortic thrombosis: A single-center case series 新生儿和婴儿主动脉血栓形成的处理:单中心病例系列。
IF 2.4 3区 医学 Q2 HEMATOLOGY Pub Date : 2024-08-16 DOI: 10.1002/pbc.31283
Ajibike Lapite, Mohammad H. Abu-Arja, Hyojeong Han, YoungNa Lee-Kim, Sarah E. Sartain, Clay T. Cohen

Neonatal and infant aortic thrombosis is a rare albeit life-threatening thrombotic event, particularly seen in premature infants with an arterial catheter in place. We describe our institutional experience and approach to the management of 11 infants with occlusive or nearly occlusive aortic thrombosis. We observed at least partial thrombus resolution in all patients. Complications related to our management included minor bleeding in two children receiving thrombolytic therapy, and two major bleeding events in children receiving anticoagulation alone. Our experience adds to the growing body of evidence that thrombolysis and thrombectomy should be considered in managing neonatal/infant aortic thrombosis.

新生儿和婴幼儿主动脉血栓是一种罕见的血栓事件,尽管会危及生命,尤其见于植入动脉导管的早产儿。我们介绍了本院治疗 11 例主动脉血栓闭塞或接近闭塞婴儿的经验和方法。我们观察到所有患者的血栓至少部分消退。与我们的治疗方法有关的并发症包括两名接受溶栓治疗的患儿出现轻微出血,两名仅接受抗凝治疗的患儿出现大出血。越来越多的证据表明,在治疗新生儿/婴儿主动脉血栓时应考虑溶栓和血栓切除术,我们的经验为这一观点增添了新的证据。
{"title":"Management of neonatal and infant aortic thrombosis: A single-center case series","authors":"Ajibike Lapite,&nbsp;Mohammad H. Abu-Arja,&nbsp;Hyojeong Han,&nbsp;YoungNa Lee-Kim,&nbsp;Sarah E. Sartain,&nbsp;Clay T. Cohen","doi":"10.1002/pbc.31283","DOIUrl":"10.1002/pbc.31283","url":null,"abstract":"<p>Neonatal and infant aortic thrombosis is a rare albeit life-threatening thrombotic event, particularly seen in premature infants with an arterial catheter in place. We describe our institutional experience and approach to the management of 11 infants with occlusive or nearly occlusive aortic thrombosis. We observed at least partial thrombus resolution in all patients. Complications related to our management included minor bleeding in two children receiving thrombolytic therapy, and two major bleeding events in children receiving anticoagulation alone. Our experience adds to the growing body of evidence that thrombolysis and thrombectomy should be considered in managing neonatal/infant aortic thrombosis.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141996249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synoptic operative reports for pediatric surgical oncology. 小儿肿瘤外科手术综合报告。
IF 2.4 3区 医学 Q2 HEMATOLOGY Pub Date : 2024-08-16 DOI: 10.1002/pbc.31280
Reto M Baertschiger, Stephanie Polites, Joseph C Fusco, Jonathan P Roach, Emily Christison-Lagay, Marcus Malek, Kenneth W Gow

Synoptic operative notes for pediatric surgical oncology provide standardized and structured documentation of surgical procedures performed on pediatric patients with cancer. These reports capture essential details such as preoperative diagnosis, intraoperative findings, surgical technique, and tumor characteristics in a concise and uniform format. By promoting consistency, accuracy, and completeness in reporting, synoptic operative notes facilitate effective communication among multidisciplinary healthcare teams, enhance quality assurance efforts, and streamline data extraction for research purposes. The integration of synoptic reporting within electronic medical record systems further enhances accessibility and usability, ensuring efficient documentation practices and improved patient care outcomes in pediatric surgical oncology.

小儿肿瘤外科综合手术笔记为小儿癌症患者提供了标准化、结构化的手术记录。这些报告以简明统一的格式记录了术前诊断、术中发现、手术技巧和肿瘤特征等重要细节。通过提高报告的一致性、准确性和完整性,同步手术记录促进了多学科医疗团队之间的有效沟通,加强了质量保证工作,并简化了用于研究目的的数据提取。将同步报告整合到电子病历系统中,可进一步提高可访问性和可用性,确保儿科肿瘤外科高效的记录实践和更好的患者护理效果。
{"title":"Synoptic operative reports for pediatric surgical oncology.","authors":"Reto M Baertschiger, Stephanie Polites, Joseph C Fusco, Jonathan P Roach, Emily Christison-Lagay, Marcus Malek, Kenneth W Gow","doi":"10.1002/pbc.31280","DOIUrl":"https://doi.org/10.1002/pbc.31280","url":null,"abstract":"<p><p>Synoptic operative notes for pediatric surgical oncology provide standardized and structured documentation of surgical procedures performed on pediatric patients with cancer. These reports capture essential details such as preoperative diagnosis, intraoperative findings, surgical technique, and tumor characteristics in a concise and uniform format. By promoting consistency, accuracy, and completeness in reporting, synoptic operative notes facilitate effective communication among multidisciplinary healthcare teams, enhance quality assurance efforts, and streamline data extraction for research purposes. The integration of synoptic reporting within electronic medical record systems further enhances accessibility and usability, ensuring efficient documentation practices and improved patient care outcomes in pediatric surgical oncology.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141996250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Symptomatic osteonecrosis in children treated for Hodgkin lymphoma: A population-based study in Sweden, Finland, and Denmark 霍奇金淋巴瘤患儿的症状性骨坏死:一项基于瑞典、芬兰和丹麦人口的研究。
IF 2.4 3区 医学 Q2 HEMATOLOGY Pub Date : 2024-08-14 DOI: 10.1002/pbc.31250
Mia Giertz, Henri Aarnivala, Sascha Wilk Michelsen, Caroline Björklund, Annika Englund, Marika Grönroos, Lisa Lyngsie Hjalgrim, Pasi Huttunen, Tuukka Niinimäki, Eva Penno, Tuuli Pöyhönen, Päivi Raittinen, Susanna Ranta, Johan E. Svahn, Lisa Törnudd, Riitta Niinimäki, Arja Harila

Background

Osteonecrosis (ON) is a potentially disabling skeletal complication of cancer treatment. Although symptomatic osteonecrosis (sON) is well-known in acute lymphoblastic leukemia (ALL), with an incidence around 6%, studies on sON in pediatric Hodgkin lymphoma (HL) are scarce. The aim of this study was to examine the incidence, risk factors, and outcome of sON in children treated for HL.

Procedure

A total of 490 children under 18, diagnosed with HL between 2005 and 2019 in Sweden, Finland, and Denmark were eligible for the study. Data on patient characteristics, HL treatment, and development of sON were collected from patients’ medical records. Magnetic resonance imaging scans were used to establish ON diagnosis and grade ON according to the Niinimäki grading system.

Results

Cumulative 2-year incidence of sON among the 489 included patients was 5.5% (n = 30). The risk for developing sON was higher for those with older age (odds ratio [OR] 1.25, 95% confidence interval [CI]: 1.05–1.49, < .010), female sex (OR 4.45, CI 1.87–10.58, < .001), high total cumulative glucocorticoid (GC) doses (OR 1.76, 95% CI: 1.21-2.56, = 0.003), and advanced HL (OR 2.19, 95% CI: 1.03-4.65, = .042). Four (13.3%) patients underwent major surgical procedures and 13 (43.3%) had persistent symptoms due to ON at follow-up.

Conclusions

This study shows that sON is as common in pediatric HL as in pediatric ALL, with risk factors such as older age, female sex, high cumulative GC doses, and advanced HL. Future HL protocol development should aim to reduce the burden of ON by modifying GC treatment.

背景:骨坏死(ON)是癌症治疗的一种潜在致残性骨骼并发症。尽管症状性骨坏死(sON)在急性淋巴细胞白血病(ALL)中的发病率约为6%,但有关小儿霍奇金淋巴瘤(HL)中症状性骨坏死的研究却很少。本研究旨在探讨接受 HL 治疗的儿童中 sON 的发生率、风险因素和结果:2005年至2019年期间,瑞典、芬兰和丹麦共有490名18岁以下儿童被诊断为HL,符合研究条件。从患者病历中收集了有关患者特征、HL治疗和sON发展的数据。磁共振成像扫描用于确诊ON,并根据Niinimäki分级系统对ON进行分级:结果:在纳入的 489 名患者中,两年内 sON 的累计发病率为 5.5%(n = 30)。年龄越大的患者发生 sON 的风险越高(赔率比 [OR] 1.25,95% 置信区间 [CI]:1.05-1.49,P<0.05):1.05-1.49, p 结论:本研究表明,sON 在小儿 HL 中与小儿 ALL 一样常见,其风险因素包括年龄较大、女性、高累积 GC 剂量和晚期 HL。未来HL治疗方案的制定应着眼于通过调整GC治疗来减轻ON的负担。
{"title":"Symptomatic osteonecrosis in children treated for Hodgkin lymphoma: A population-based study in Sweden, Finland, and Denmark","authors":"Mia Giertz,&nbsp;Henri Aarnivala,&nbsp;Sascha Wilk Michelsen,&nbsp;Caroline Björklund,&nbsp;Annika Englund,&nbsp;Marika Grönroos,&nbsp;Lisa Lyngsie Hjalgrim,&nbsp;Pasi Huttunen,&nbsp;Tuukka Niinimäki,&nbsp;Eva Penno,&nbsp;Tuuli Pöyhönen,&nbsp;Päivi Raittinen,&nbsp;Susanna Ranta,&nbsp;Johan E. Svahn,&nbsp;Lisa Törnudd,&nbsp;Riitta Niinimäki,&nbsp;Arja Harila","doi":"10.1002/pbc.31250","DOIUrl":"10.1002/pbc.31250","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Osteonecrosis (ON) is a potentially disabling skeletal complication of cancer treatment. Although symptomatic osteonecrosis (sON) is well-known in acute lymphoblastic leukemia (ALL), with an incidence around 6%, studies on sON in pediatric Hodgkin lymphoma (HL) are scarce. The aim of this study was to examine the incidence, risk factors, and outcome of sON in children treated for HL.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Procedure</h3>\u0000 \u0000 <p>A total of 490 children under 18, diagnosed with HL between 2005 and 2019 in Sweden, Finland, and Denmark were eligible for the study. Data on patient characteristics, HL treatment, and development of sON were collected from patients’ medical records. Magnetic resonance imaging scans were used to establish ON diagnosis and grade ON according to the Niinimäki grading system.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Cumulative 2-year incidence of sON among the 489 included patients was 5.5% (<i>n</i> = 30). The risk for developing sON was higher for those with older age (odds ratio [OR] 1.25, 95% confidence interval [CI]: 1.05–1.49, <i>p </i>&lt; .010), female sex (OR 4.45, CI 1.87–10.58, <i>p </i>&lt; .001), high total cumulative glucocorticoid (GC) doses (OR 1.76, 95% CI: 1.21-2.56, <i>p </i>= 0.003), and advanced HL (OR 2.19, 95% CI: 1.03-4.65, <i>p </i>= .042). Four (13.3%) patients underwent major surgical procedures and 13 (43.3%) had persistent symptoms due to ON at follow-up.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study shows that sON is as common in pediatric HL as in pediatric ALL, with risk factors such as older age, female sex, high cumulative GC doses, and advanced HL. Future HL protocol development should aim to reduce the burden of ON by modifying GC treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.31250","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141976317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contemporary surgical management of pediatric non-rhabdomyosarcoma soft tissue sarcoma 小儿非横纹肌肉瘤软组织肉瘤的当代外科治疗。
IF 2.4 3区 医学 Q2 HEMATOLOGY Pub Date : 2024-08-13 DOI: 10.1002/pbc.31257
Stephanie F. Polites, Daniel S. Rhee, Guido Seitz, Patrizia Dall'Igna, Odion Binitie, Thomas Scharschmidt, Timothy B. Lautz, Roshni Dasgupta

Non-rhabdomyosarcoma soft tissue sarcoma (STS) comprises most STS in pediatric patients. It is a diverse set of over 30 histologic subtypes. Treatment is based on risk group determined by tumor size, grade, and the presence of metastases. Surgical resection is a cornerstone of therapy, as tumors are often resistant to chemotherapy or radiation. While patients with isolated tumors less than 5 cm may undergo upfront resection, strong consideration should be given to neoadjuvant chemoradiotherapy to ensure negative margins at surgical resection and optimal outcomes. Sentinel lymph node biopsy is strongly recommended for clear cell and epithelioid sarcomas. The most common metastatic site is the lung, and metastases should be resected at the end of therapy, when feasible. Unfortunately, many high-risk patients progress on therapy, and alternative strategies including earlier metastatic control require investigation.

非横纹肌肉瘤软组织肉瘤(STS)是儿童患者中的大多数 STS。它由 30 多种组织学亚型组成。治疗是根据肿瘤大小、分级和有无转移来确定风险组别。手术切除是治疗的基础,因为肿瘤通常对化疗或放疗有抵抗力。虽然小于 5 厘米的孤立肿瘤患者可以接受前期切除术,但应着重考虑新辅助化放疗,以确保手术切除时的阴性边缘和最佳疗效。强烈建议对透明细胞肉瘤和上皮样肉瘤进行前哨淋巴结活检。最常见的转移部位是肺部,在可行的情况下,应在治疗结束时切除转移灶。遗憾的是,许多高危患者的病情在治疗过程中不断恶化,因此需要研究包括早期转移控制在内的替代策略。
{"title":"Contemporary surgical management of pediatric non-rhabdomyosarcoma soft tissue sarcoma","authors":"Stephanie F. Polites,&nbsp;Daniel S. Rhee,&nbsp;Guido Seitz,&nbsp;Patrizia Dall'Igna,&nbsp;Odion Binitie,&nbsp;Thomas Scharschmidt,&nbsp;Timothy B. Lautz,&nbsp;Roshni Dasgupta","doi":"10.1002/pbc.31257","DOIUrl":"10.1002/pbc.31257","url":null,"abstract":"<p>Non-rhabdomyosarcoma soft tissue sarcoma (STS) comprises most STS in pediatric patients. It is a diverse set of over 30 histologic subtypes. Treatment is based on risk group determined by tumor size, grade, and the presence of metastases. Surgical resection is a cornerstone of therapy, as tumors are often resistant to chemotherapy or radiation. While patients with isolated tumors less than 5 cm may undergo upfront resection, strong consideration should be given to neoadjuvant chemoradiotherapy to ensure negative margins at surgical resection and optimal outcomes. Sentinel lymph node biopsy is strongly recommended for clear cell and epithelioid sarcomas. The most common metastatic site is the lung, and metastases should be resected at the end of therapy, when feasible. Unfortunately, many high-risk patients progress on therapy, and alternative strategies including earlier metastatic control require investigation.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141976311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Documentation of critical intraoperative oncologic findings: Synoptic versus narrative operative reports for childhood cancer surgery 记录关键的术中肿瘤学发现:儿童癌症手术的综合与叙述性手术报告。
IF 2.4 3区 医学 Q2 HEMATOLOGY Pub Date : 2024-08-13 DOI: 10.1002/pbc.31269
Abdelhafeez H. Abdelhafeez, Zachary Morrison, Huma F. Halepota, Brian Hosfield, Lindsey J. Talbot, Andrew J. Murphy, Andrew M. Davidoff

Background

Documentation of intraoperative oncologic findings varies greatly across narrative operative reports (NRs). An international panel of childhood cancer experts recently developed a synoptic operative report (SR) for childhood cancer surgeries. The aim of this study was to compare the documentation of critical intraoperative findings in NRs versus SRs.

Methods

A single-center retrospective review of all surgical resections of primary solid tumors at our pediatric oncology center was conducted from June 2023 to March 2024, after an institutional SR was piloted from October 2023 onwards. Data collected included the presence or absence of six components included in standard pediatric oncology NRs. Inclusion rates were calculated as percentages for each component. Due to the small sample, the Fisher's exact test was used for all hypothesis testing.

Results

Seventy primary tumor resections were performed during the study period, as documented by 38 NRs and 32 SRs. All operative reports after October 2023 were SRs. Completeness of tumor resection and specimen naming were consistently documented in NRs (86% and 100%, respectively) and SRs (100% and 100%, respectively). The presence/absence of three components—intraoperative tumor spillage (31%), vascular involvement (31%), and lymph node sampling (26%)—were documented in fewer than a third of the NRs. Documentation of the presence/absence of locoregional spread, intraoperative tumor spillage, vascular involvement, and lymph node sampling was significantly better in SRs than in NRs.

Conclusion

Adoption of SRs significantly improved the documentation of critical intraoperative findings. Thus, we recommend using SRs in pediatric solid tumor surgery.

背景:不同的叙述性手术报告(NR)对术中肿瘤学发现的记录差异很大。最近,一个由儿童癌症专家组成的国际小组为儿童癌症手术制定了一份综合手术报告(SR)。本研究的目的是比较 NR 与 SR 中关键术中发现的记录情况:方法:自 2023 年 10 月开始试行机构 SR 后,我们在 2023 年 6 月至 2024 年 3 月期间对儿童肿瘤中心的所有原发性实体瘤手术切除进行了单中心回顾性审查。收集的数据包括是否包含标准儿科肿瘤 NR 中的六项内容。每项内容的纳入率均按百分比计算。由于样本较少,所有假设检验均采用费雪精确检验:根据 38 份 NR 和 32 份 SR 的记录,研究期间共进行了 70 例原发性肿瘤切除术。2023 年 10 月之后的所有手术报告均为 SR。NR(分别为86%和100%)和SR(分别为100%和100%)均记录了肿瘤切除和标本命名的完整性。只有不到三分之一的 NR 记录了肿瘤术中溢出(31%)、血管受累(31%)和淋巴结取样(26%)三项内容的存在/不存在。在记录有/无局部扩散、术中肿瘤溢出、血管受累和淋巴结取样方面,SR 明显优于 NR:结论:采用SR能明显改善对术中重要发现的记录。因此,我们建议在小儿实体瘤手术中使用 SR。
{"title":"Documentation of critical intraoperative oncologic findings: Synoptic versus narrative operative reports for childhood cancer surgery","authors":"Abdelhafeez H. Abdelhafeez,&nbsp;Zachary Morrison,&nbsp;Huma F. Halepota,&nbsp;Brian Hosfield,&nbsp;Lindsey J. Talbot,&nbsp;Andrew J. Murphy,&nbsp;Andrew M. Davidoff","doi":"10.1002/pbc.31269","DOIUrl":"10.1002/pbc.31269","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Documentation of intraoperative oncologic findings varies greatly across narrative operative reports (NRs). An international panel of childhood cancer experts recently developed a synoptic operative report (SR) for childhood cancer surgeries. The aim of this study was to compare the documentation of critical intraoperative findings in NRs versus SRs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A single-center retrospective review of all surgical resections of primary solid tumors at our pediatric oncology center was conducted from June 2023 to March 2024, after an institutional SR was piloted from October 2023 onwards. Data collected included the presence or absence of six components included in standard pediatric oncology NRs. Inclusion rates were calculated as percentages for each component. Due to the small sample, the Fisher's exact test was used for all hypothesis testing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seventy primary tumor resections were performed during the study period, as documented by 38 NRs and 32 SRs. All operative reports after October 2023 were SRs. Completeness of tumor resection and specimen naming were consistently documented in NRs (86% and 100%, respectively) and SRs (100% and 100%, respectively). The presence/absence of three components—intraoperative tumor spillage (31%), vascular involvement (31%), and lymph node sampling (26%)—were documented in fewer than a third of the NRs. Documentation of the presence/absence of locoregional spread, intraoperative tumor spillage, vascular involvement, and lymph node sampling was significantly better in SRs than in NRs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Adoption of SRs significantly improved the documentation of critical intraoperative findings. Thus, we recommend using SRs in pediatric solid tumor surgery.</p>\u0000 </section>\u0000 </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141976312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oncofertility care for children, adolescents, and young adults at risk for treatment-related fertility loss. 为有可能因治疗而丧失生育能力的儿童、青少年和年轻人提供肿瘤不孕不育护理。
IF 2.4 3区 医学 Q2 HEMATOLOGY Pub Date : 2024-08-13 DOI: 10.1002/pbc.31277
Lindsay Talbot, Kristine S Corkum, Kate McCracken, Nicholas G Cost, Jennifer H Aldrink

As therapy for childhood malignancies becomes more sophisticated and survival has improved, long-term therapy-related sequelae have emerged. Loss of reproductive potential among childhood cancer survivors is one such concern that has become increasingly recognized among patients, families, and healthcare providers. The risk status for infertility based upon therapy received, state of current reproductive technology and outcomes, and an emphasis on adequate referral and counseling for fertility preservation options are reviewed. Contributing factors to infertility are discussed, and options for female and male preservation based upon age and pubertal status are summarized. This article highlights the current state of fertility opportunities for children and adolescents undergoing therapy for cancer. Providers caring for these young patients should be familiar with such options and should routinely initiate evaluations for eligibility of fertility preservation.

随着儿童恶性肿瘤治疗的日益成熟和生存率的提高,出现了与长期治疗相关的后遗症。儿童癌症幸存者丧失生殖潜能就是患者、家属和医疗服务提供者日益关注的问题之一。本文回顾了基于所接受治疗的不孕不育风险状况、当前生殖技术的发展状况和结果,并强调了适当的转诊和生育力保存方案咨询。文章讨论了导致不孕不育的因素,并根据年龄和青春期状况总结了女性和男性保留生育力的选择。本文重点介绍了接受癌症治疗的儿童和青少年的生育机会现状。为这些年轻患者提供护理的医疗人员应熟悉这些选择,并应常规启动生育能力保留资格的评估。
{"title":"Oncofertility care for children, adolescents, and young adults at risk for treatment-related fertility loss.","authors":"Lindsay Talbot, Kristine S Corkum, Kate McCracken, Nicholas G Cost, Jennifer H Aldrink","doi":"10.1002/pbc.31277","DOIUrl":"https://doi.org/10.1002/pbc.31277","url":null,"abstract":"<p><p>As therapy for childhood malignancies becomes more sophisticated and survival has improved, long-term therapy-related sequelae have emerged. Loss of reproductive potential among childhood cancer survivors is one such concern that has become increasingly recognized among patients, families, and healthcare providers. The risk status for infertility based upon therapy received, state of current reproductive technology and outcomes, and an emphasis on adequate referral and counseling for fertility preservation options are reviewed. Contributing factors to infertility are discussed, and options for female and male preservation based upon age and pubertal status are summarized. This article highlights the current state of fertility opportunities for children and adolescents undergoing therapy for cancer. Providers caring for these young patients should be familiar with such options and should routinely initiate evaluations for eligibility of fertility preservation.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141976315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Foreign patients and multicultural challenges in pediatric oncology: The experience of the Istituto Nazionale dei Tumori in Milan 儿科肿瘤学中的外国患者和多元文化挑战:米兰国家肿瘤研究所的经验。
IF 2.4 3区 医学 Q2 HEMATOLOGY Pub Date : 2024-08-13 DOI: 10.1002/pbc.31260
Martina Lombardi, Matteo Silva, Monica Giovanetti, Daniele Cabibbe, Roberto Luksch, Monica Terenziani, Michela Casanova, Filippo Spreafico, Cristina Meazza, Marta Podda, Veronica Biassoni, Elisabetta Schiavello, Stefano Chiaravalli, Nadia Puma, Luca Bergamaschi, Giovanna Gattuso, Olga Nigro, Giovanna Sironi, Valeria Colombo, Andrea Ferrari, Maura Massimino, Carlo Alfredo Clerici

This paper describes the complexity of the clinical management of foreign minors suffering from cancer, through the clinical experience of an Italian referral center. The study includes 50 patients less than 18 years (22% of the patients admitted to the unit in 2023), 32 foreigners who were Italian resident and 18 who had come to Italy specifically to receive cancer treatment. Patients who migrate for healthcare reasons often arrive at the referral center with advanced disease or relapse. Numerous socio-cultural issues were reported. To address them, specific strategies were implemented to ensure equal and high-quality care for all patients, respecting their needs.

本文通过意大利一家转诊中心的临床经验,阐述了外籍未成年人癌症患者临床管理的复杂性。研究对象包括 50 名年龄小于 18 岁的患者(占 2023 年该中心收治患者的 22%)、32 名居住在意大利的外籍人士和 18 名专程来意大利接受癌症治疗的患者。因医疗保健原因而移民的患者来到转诊中心时往往已是晚期或病情复发。报告中提到了许多社会文化问题。为解决这些问题,实施了具体战略,以确保为所有患者提供平等和高质量的护理,并尊重他们的需求。
{"title":"Foreign patients and multicultural challenges in pediatric oncology: The experience of the Istituto Nazionale dei Tumori in Milan","authors":"Martina Lombardi,&nbsp;Matteo Silva,&nbsp;Monica Giovanetti,&nbsp;Daniele Cabibbe,&nbsp;Roberto Luksch,&nbsp;Monica Terenziani,&nbsp;Michela Casanova,&nbsp;Filippo Spreafico,&nbsp;Cristina Meazza,&nbsp;Marta Podda,&nbsp;Veronica Biassoni,&nbsp;Elisabetta Schiavello,&nbsp;Stefano Chiaravalli,&nbsp;Nadia Puma,&nbsp;Luca Bergamaschi,&nbsp;Giovanna Gattuso,&nbsp;Olga Nigro,&nbsp;Giovanna Sironi,&nbsp;Valeria Colombo,&nbsp;Andrea Ferrari,&nbsp;Maura Massimino,&nbsp;Carlo Alfredo Clerici","doi":"10.1002/pbc.31260","DOIUrl":"10.1002/pbc.31260","url":null,"abstract":"<p>This paper describes the complexity of the clinical management of foreign minors suffering from cancer, through the clinical experience of an Italian referral center. The study includes 50 patients less than 18 years (22% of the patients admitted to the unit in 2023), 32 foreigners who were Italian resident and 18 who had come to Italy specifically to receive cancer treatment. Patients who migrate for healthcare reasons often arrive at the referral center with advanced disease or relapse. Numerous socio-cultural issues were reported. To address them, specific strategies were implemented to ensure equal and high-quality care for all patients, respecting their needs.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.31260","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141976314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ewing sarcoma among children 5 years of age or younger: Is it a different disease? 5 岁或以下儿童的尤文肉瘤:这是一种不同的疾病吗?
IF 2.4 3区 医学 Q2 HEMATOLOGY Pub Date : 2024-08-13 DOI: 10.1002/pbc.31268
Chitrakshi Nagpal, Shuvadeep Ganguly, Archana Sasi, Vivek Kumar, Bivas Biswas, Deepam Pushpam, Akash Kumar, Sandeep Agarwala, Vishesh Jain, Anjan Dhua, Devender Kumar Yadav, Shah Alam Khan, Adarsh Barwad, Asit Ranjan Mirdha, Ahitagni Biswas, Sanjay Thulkar, Sameer Bakhshi

Introduction

Children ≤5 years of age with Ewing's sarcoma (ES) possibly have a distinct disease biology, data on which are scarce. We evaluated clinical features, outcomes, and prognostic factors of ES among children with age ≤5 years.

Methods

Children with ES registered between 2003 and 2019 were included. Baseline clinical and treatment details were retrieved from medical records. Prognostic factors were identified using multivariable Cox regression. Clinical features and outcomes of children ≤5 years were compared with those greater than 5 years by chi-square and log-rank tests. Propensity score-matched (PSM) analysis was done to evaluate the impact of age on survival in the metastatic and localized subgroups.

Results

Out of the 859 patients, 86 (10%) were ≤5 years of age (median age 4 years, 60 males [69.8%]). The most common location was the extremities (37.2%), followed by thorax (27.9%) and head and neck (H&N) (22.1%); baseline metastases were seen in 25 patients (29.8%). The median event-free-survival (EFS) and overall survival (OS) were 25.6 and 68.7 months, respectively. Metastatic disease predicted inferior OS (hazard ratio [HR] = 2.54, p = .018) and EFS (HR = 2.47, p = .007], symptom duration ≤3 months predicted an inferior OS (HR = 2.17, p = .048). Compared to age greater than 5 years, younger children had more H&N and less pelvic primaries (p < .001) and lesser baseline metastases (p = .037). PSM analysis did not reveal any significant impact of age on OS in the metastatic (HR = 1.59, p = .29) or localized cohort (HR = 1.77, p = .09).

Conclusions

Children with ES ≤5 years of age have a distinct favorable clinical presentation. However, age is not an independent prognostic factor for survival outcomes when adjusted for confounders.

导言:罹患尤文氏肉瘤(ES)的5岁以下儿童可能具有独特的疾病生物学特性,但相关数据却很少。我们评估了5岁以下儿童尤文氏肉瘤的临床特征、结局和预后因素:方法:纳入 2003 年至 2019 年期间登记的 ES 儿童。从医疗记录中检索基线临床和治疗细节。使用多变量 Cox 回归确定预后因素。通过卡方检验(chi-square)和对数秩检验(log-rank)比较≤5岁和大于5岁儿童的临床特征和预后。进行倾向得分匹配(PSM)分析,以评估年龄对转移亚组和局部亚组生存率的影响:在859名患者中,86人(10%)的年龄小于5岁(中位年龄为4岁,男性60人[69.8%])。最常见的部位是四肢(37.2%),其次是胸部(27.9%)和头颈部(22.1%);25 名患者(29.8%)出现基线转移。中位无事件生存期(EFS)和总生存期(OS)分别为25.6个月和68.7个月。转移性疾病预示着较差的OS(危险比[HR] = 2.54,P = .018)和EFS(HR = 2.47,P = .007),症状持续时间≤3个月预示着较差的OS(HR = 2.17,P = .048)。与年龄大于 5 岁的儿童相比,年龄较小的儿童有更多的 H&N 和更少的骨盆原发灶(P5岁以下ES患儿的临床表现明显良好。然而,在对混杂因素进行调整后,年龄并不是影响生存结果的独立预后因素。
{"title":"Ewing sarcoma among children 5 years of age or younger: Is it a different disease?","authors":"Chitrakshi Nagpal,&nbsp;Shuvadeep Ganguly,&nbsp;Archana Sasi,&nbsp;Vivek Kumar,&nbsp;Bivas Biswas,&nbsp;Deepam Pushpam,&nbsp;Akash Kumar,&nbsp;Sandeep Agarwala,&nbsp;Vishesh Jain,&nbsp;Anjan Dhua,&nbsp;Devender Kumar Yadav,&nbsp;Shah Alam Khan,&nbsp;Adarsh Barwad,&nbsp;Asit Ranjan Mirdha,&nbsp;Ahitagni Biswas,&nbsp;Sanjay Thulkar,&nbsp;Sameer Bakhshi","doi":"10.1002/pbc.31268","DOIUrl":"10.1002/pbc.31268","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Children ≤5 years of age with Ewing's sarcoma (ES) possibly have a distinct disease biology, data on which are scarce. We evaluated clinical features, outcomes, and prognostic factors of ES among children with age ≤5 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Children with ES registered between 2003 and 2019 were included. Baseline clinical and treatment details were retrieved from medical records. Prognostic factors were identified using multivariable Cox regression. Clinical features and outcomes of children ≤5 years were compared with those greater than 5 years by chi-square and log-rank tests. Propensity score-matched (PSM) analysis was done to evaluate the impact of age on survival in the metastatic and localized subgroups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Out of the 859 patients, 86 (10%) were ≤5 years of age (median age 4 years, 60 males [69.8%]). The most common location was the extremities (37.2%), followed by thorax (27.9%) and head and neck (H&amp;N) (22.1%); baseline metastases were seen in 25 patients (29.8%). The median event-free-survival (EFS) and overall survival (OS) were 25.6 and 68.7 months, respectively. Metastatic disease predicted inferior OS (hazard ratio [HR] = 2.54, <i>p</i> = .018) and EFS (HR = 2.47, <i>p</i> = .007], symptom duration ≤3 months predicted an inferior OS (HR = 2.17, <i>p</i> = .048). Compared to age greater than 5 years, younger children had more H&amp;N and less pelvic primaries (<i>p</i> &lt; .001) and lesser baseline metastases (<i>p</i> = .037). PSM analysis did not reveal any significant impact of age on OS in the metastatic (HR = 1.59, <i>p</i> = .29) or localized cohort (HR = 1.77, <i>p</i> = .09).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Children with ES ≤5 years of age have a distinct favorable clinical presentation. However, age is not an independent prognostic factor for survival outcomes when adjusted for confounders.</p>\u0000 </section>\u0000 </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141976313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pediatric Blood & Cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1